Health
UNDERREPORTED
Late-stage mRNA vaccine halts melanoma recurrence, sparking new cancer hopes
A late-stage trial showed Merck and Moderna’s mRNA melanoma vaccine, intismeran autogene, delayed disease return, reviving optimism for broader cancer use.
Merck and Moderna announced that adding their mRNA vaccine intismeran autogene to standard therapy slowed melanoma relapse and spread in a late-stage study. The result was hailed by Karen Knudsen of the Parker Institute for Cancer Immunotherapy as a breakthrough for messenger-RNA-based cancer treatments. The finding renews expectations that the technology could be adapted to target other tumor types.
Why it matters
The trial suggests mRNA vaccines could become a versatile tool against multiple cancers, not just melanoma.
In this story
mRNA cancer vaccinemelanomaintismeran autogeneclinical trialcancer immunotherapyMerckModernaParker Institute
